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Abstract
There is increasing scientific evidence that human umbilical cord cells are a valuable
source of adult stem cells that can be used for various implications including regener-
ative medicine and tissue engineering. The review describes the role of progenitor cells
(mesenchymal, endothelial, prenatal) for the use in cardiovascular tissue engineering,
i.e., the formation of large vessels and heart valves from umbilical cord cells.
Currently used replacements in cardiovascular surgery are made of foreign materi-
als with well known drawbacks such as thrombo-embolic complications, infection, loss
of functional and biological properties, and others. Especially in the field of replace-
ments in congenital cardiac defects, there would be a need of materials which have the
advantage of optimal biological and mechanical properties. In the case of human umbil-
ical cord cells, autologous cells can be used by minimally invasive procedures. The cells
have excellent growth capacities and form a neo-matrix with excellent mechanical prop-
erties. For optimal growth and modeling, scaffolds are required with high biocompat-
ibility and biodegradability, which allow cell attachment, ingrowth, and organization.
Nutrients and waste must be easily transported and cells should be in entire contact
with host’s body. Finally, regenerated materials can be fully incorporated and the scaf-
fold is completely replaced. Besides these cell and scaffold requirements, feto-maternal
conditions and risk factors concerning deriving stem cells are of major interest. There
are still many open questions concerning whether and how maternal conditions such
as infection (viral or bacterial) or gestational age of the newborn influence stem cell har-
vesting and quality. If these cells will be used for the construction of replacement mate-
rials, it is clear that very strict criteria and protocols be introduced enabling the promising
step from isolated cells to a therapeutic device such as a new heart valve. It is hoped
that it will be only a question of time until human umbilical cord cells will be used fre-
quently as the source of cardiovascular tissues among others in the clinical setting of
treating congenital heart defects.
Index Entries: Human umbilical cord; stem cells; tissue engineering; cardiovascular;
heart defect; congenital.
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tissue damage or destruction in an in vivo
environment, they can be recruited from
several sources for example, bone marrow,
blood, or as resident stem cell from the
injured tissue itself in order to start the cas-
cade for tissue repair. 
Introduction
To date, it is well known and evident
that adult stem cells, also named progeni-
tor cells, play an important role in regen-
erative medicine and even enable the
mechanisms of tissue regeneration. After
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More than 30,000 articles have been published on stem cell
research demonstrating the increased interest in this field. The
dynamics of stem cell research have been driven particularly by
tissue engineering as a major discipline in regenerative medi-
cine with focus on various organs such as skin, bone and carti-
lage tissue, urinary tract system, liver parenchyma, eyes,
neuronal tissue, and finally the cardiovascular system.
Furthermore, there is an increasing interest among the public
and the mass media and it seems only to be a matter of time
until tissue engineering reaches the routine medical practice (1).
In this review, a short summary regarding to the role of pro-
genitor cells derived from umbilical cord for cardiovascular
tissue engineering is presented. The umbilical cord provides
various types of progenitor cells including umbilical cord-
derived mesenchymal cells, endothelial progenitor cells (EPC),
and cells from the Wharton’s jelly tissue (2). Thus, using human
umbilical cord (hUC)-derived cells could be an attractive con-
cept for regenerative medicine. This will be highlighted in
another article in this issue by C. Cetrulo. 
The Potential Role of Umbilical 
Cord-Derived Cells in Cardiovascular 
Tissue Engineering 
Cardiovascular tissue engineering, focuses on the in vitro
fabrication of autologous, living tissues. This has potential for
regeneration and is a promising scientific field, addressing the
so far unmet medical need for growing replacements, partic-
ularly for the repair of congenital malformation.
Currently used replacements are nonliving and based on
foreign materials. They exhibit lack of growth and remodel-
ing, and also carry the risks for thrombo-embolic complica-
tions and infections. Particularly, in today’s congenital heart
surgery, there is a substantial need for appropriate, growing
replacement materials for the repair of congenital cardiac
defects. The surgical treatment is commonly based on nonau-
tologous valves or conduits (3,4) with disadvantages including
obstructive tissue ingrowths and calcification of the replace-
ment. These limitations and the lack of growth typically neces-
sitate various reoperations of the pediatric patients with
cardiovascular defects and each time they are associated with
increased morbidity and mortality.
Tissue-engineered constructs based on umbilical cord-
derived cells could be an attractive alternative to the current
replacement materials for the repair of congenital malforma-
tions. Being living material and owing to their progenitor char-
acteristics having the capacity of self-remodeling. Here,
umbilical cord-derived cells would be ideal for tissue-
engineered constructs as they can be harvested without harm-
ing intact donor structures and high risks for the child. The
advantages of using umbilical cord-derived cells are sum-
marized in Table 1.
The Concept of In Vitro Generating 
of Umbilical Cord-Derived Cell Based
Cardiovascular Replacements 
Tissue engineering using umbilical cord-derived cells could
enable living autologous replacement structures including vas-
cular grafts and heart valves. Therefore, cells could be harvested
from the umbilical cord, differentiated and expanded in vitro.
Table 1
Advantages of Using hUC-Derived Cells for Cardiovascular
Tissue Engineering
• Autologous cells source
• Minimally invasive obtainable
• Cell source providing different types of cells including pro-
genitor cells
• Excellent cell growth capacities
• Forming an optimal neo-matrix with excellent mechanical
properties
In order to fabricate the cardiovascular constructs, cells should
be seeded onto biodegradable scaffold that are implanted into
a biomimetic system (bioreactor). The tissue formation and
maturation would have been accelerated (5). After 14 d, suffi-
cient tissue formation should have been taken place and the
constructs should be ready for implantation.
In order to create a functional heart valve with the mechan-
ical properties of the native counterpart, rapid development
of the extracellular matrix is crucial. Therefore, the choice of
cells, which are responsible for the production of extracellu-
lar matrix is an important factor. Two cell types are routinely
used for the fabrication of cardiovascular tissues: cells with
the capacity to form extracellular matrix (commonly myofi-
broblasts) and endothelial cells with antithrombogenic char-
acteristics. The seeding procedure is mostly performed
sequentially onto three-dimensional scaffolds: first, by seed-
ing of the myofibroblasts and then followed by the endothe-
lial cells (6). From umbilical cord, myofibroblast could be
obtained from its vessels or Wharton’s jelly. Endothelial cells
could be isolated either from the vessels or alternatively from
the umbilical cord blood.
As a temporary vehicle for cells, biodegradable scaffolds
can be used in cardiovascular tissue engineering. Possible prob-
lems concerning these systems are systemic toxicity, growth
limitation, differentiation and function restraints, incorpora-
tion barriers, and cell or tissue delivery difficulties.
The ideal scaffold would have a high porosity and inter-
connected pores with pore size between 100 and 150 µm
enabling cell differentiation and ingrowth, diffusion of nutri-
ents and waste as well as the contact between cells and the
host’s body. The scaffold material should be biodegradable.
Mechanical strength with controlled degradation is necessary,
which enables elastic properties up to strains of 10%. Numerous
scaffolds have been used and tested such as: PGA, PLA, P3HB,
P4HB, Degrapol, PGA + P4HB, PGA + Degrapol, and PGA +
PCL). Scaffold requirements are listed in Table 2.
In general the concept of cardiovascular tissue engineer-
ing has been already validated in large animal studies (7).
Completely autologous, living trileaflet heart valve has been
successfully implanted in a growing sheep model for up to
20 wk. These valves showed good functional performance
as well as structural and biomechanical characteristics
strongly resembling those of native semilunar heart valves.
The first clinical application of a tissue-engineered pul-
monary artery graft in a pediatric patient was reported by
Shinoka et al (8). However, long-term results have not been
presented so far.
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Summary of Own Research in the Field
Since 2001, human umbilical cord cells (hUCC) were inves-
tigated in a cooperation project as a source of cardiovascular
tissue engineering. Umbilical cord tissues and blood were
sampled in the obstetric department according to a fixed pro-
tocol for the obstetric patients undergoing elective caesarean
delivery (Table 3).
After cell isolation and cultivation, cells are seeded on the
bioabsorbable scaffold for 4–6 wk and in vitro cultured in a
pulse duplicator culture environment which mimics circula-
tory characteristics (bioreactor) and therefore accelerates tis-
sue formation and maturation (Table 4). The analysis of the cells
and derived tissue-engineered implants are listed in Table 5. 
Chronological Course of Studies
In 2002, the feasibility of using umbilical cord cells (UCC)
as an alternative autologous cell source for cardiovascular tis-
sue engineering was investigated. The feasibility of creating
pulmonary artery conduits from hUCC was investigated (9,10).
Methods
The hUCCs were harvested and expanded in culture.
Pulmonary conduits fabricated from rapidly bioabsorbable
polymers were seeded with hUCC and grown in vitro in a
pulse duplicator bioreactor. 
Morphological characterization of the generated neo-tis-
sues included histology, transmission, and scanning electron
microscopy. Characterization of extracellular matrix was
performed by immunohistochemistry. Extracellular matrix
protein content and cell proliferation were quantified by bio-
chemical assays. Biomechanical testing was performed using
stress–strain and burst–stress tests.
Results
Histology of the conduits revealed viable, layered tissue, and
extracellular matrix formation with glycosaminoglycans and col-
lagens I and III. Cells stained positive for vimentin and α-smooth
muscle actin (ASMA). Scanning electron microscopy showed
confluent homogenous tissue surfaces. Transmission electron-
microscopy demonstrated elements typical of viable myofi-
broblasts, such as collagen, fibrils, and elastin (Fig. 1). Extracellular
matrix proteins were significantly lower compared with native
tissue and increase in the cell content was increased. The mechan-
ical strength of the pulsed constructs was comparable with native
tissue; the static controls were significantly weaker.
Table 2
Requirements of an Ideal Scaffold
• Biocompatibility
• Biodegradability
• Allowing cell attachment, ingrowth, and cell organization
• Diffusion of nutrients and waste
• Cells in contact with host’s body
• Full incorporation and replacement
Table 3
Obstetric Patients and Procedure 
for Umbilical Cord Sampling
• Elective caesarean section.
• Term birth (>37 WOG)
• Normal feto-maternal history
• Normale bacterial and serological testing
• No amnion rupture, no sign of amnion infection
• Umbilical cord and cord blood sampling in 5 min period
after clamping
 10 mL Hank solution with ethylenediamine tetra-acetic
acid
 Medium: DMEM (Dulbecco’s medium)
Table 4
Steps in Tissue Engineering From hUCC
• Cell isolation and cultivation
• Bioabsorbable scaffold (4–6 wk)
• Cell seeding, in vitro culture
• Pulse duplicator culture environment
 “Bioreactor”
 Accelerates tissue formation and maturation
Table 5
Analysis of Tissue-Engineered Structures
• Flow cytometry
 ASMA
 Vimentin
• Histology, immunohistochemistry
 Collagen, AMSA, vimentin
• Micro- and ultrastructure
• Quantitative analysis
 Comparison with native tissue
• Biomechanical analysis
 Mechanical properties
Fig. 1. Flow cytometry of human saphenous vein-derived cells (upper
panel) and hUC-derived cells demonstrates a similar staining pattern
for the expression of vimentin and α-smooth muscle actin.
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Conclusions
In vitro fabrication of tissue-engineered human pulmonary
conduits was feasible utilizing hUCC and a biomimetic cul-
ture environment. Morphological and mechanical features
approximated human pulmonary artery. The hUCC demon-
strated excellent growth properties representing a new, readily
available cell source for tissue engineering without necessi-
tating the sacrifice of intact vascular donor structures.
In 2004 the results from testing of various umbilical tissues
as sources for tissue engineering were published (11). This study
evaluated cells isolated from human umbilical cord artery (UCA),
umbilical cord vein (UCV), and whole cord as alternative autol-
ogous cell sources for cardiovascular tissue engineering. 
Methods
Cells were isolated from UCA, UCV, UCC, and saphenous
vein segments (VC) from adults, and were expanded in culture.
All three expanded cell groups were seeded on bioabsorbable
copolymer strips and were grown in vitro for 28 d. Isolated cells
were characterized by flow cytometry, histology, immunohisto-
chemistry, proliferation assays and compared to VC. Morpho-
logical analysis of the seeded polymer strips included histology,
immunohistochemistry, sodium dodecyl sulfate-polyacrylamide
gel electrophoresis, transmission electron microscopy, scanning
electron microscopy, and uniaxial stress testing. 
Results
UCA, UCV, and UCC demonstrated excellent cell growth
properties comparable to VC. Following isolation, all three cell
groups showed myofibroblast-like morphology and charac-
teristics by staining positive for ASMAand vimentin. Histology
and immunohistochemistry of seeded polymers showed good
tissue and extracellular matrix formation containing collagen I,
collagen III, and elastin. Transmission electron microscopy
showed viable myofibroblasts and the deposition of collagen
fibrils and progessive growing tissue formation, with a con-
fluent surface, was observed in scanning electron microscopy.
No difference was found among the mechanical properties of
UCA, UCV, UCC, and VC tissue-engineered constructs. 
Conclusions
Tissue engineering of cardiovascular constructs by using
UCA, UCV, and UCC is feasible in an in vitro environment.
Cell growth, morphology, characteristics and tissue formation
were comparable between UCA, UCV, UCC, and VC. UCC
represent an attractive, readily available autologous cell source
for cardiovascular, tissue engineering offering the additional
benefits of utilizing juvenile cells and avoiding the invasive
harvesting of intact vascular structures.
As a next step, it was interesting to investigate EPC from
umbilical cord blood as a source for cardiovascular tissue engi-
neering (12). Here, tissue-engineered vascular grafts using hUC
blood-derived EPCs, as a prenatal available cell source for
pediatric applications were focussed.
Methods
EPCs were isolated from 20 mL fresh hUC blood by gradi-
ent centrifugation and cultured in endothelial basal medium
containing growth factors. 
After proliferation and differentiation cells were analyzed
by immunohistochemistry and seeded onto three-dimensional
biodegradable vascular scaffolds (porosity >95%, n = 22).
Twenty-four hours after seeding, the vascular grafts were
positioned into a pulse-duplicator in vitro system and grown
for 48 h under biomimetic conditions. Asecond group was grown
6 d statically and an additional 6 d biomimetically. Controls
were cultured statically. Analysis of the grafts included immuno-
histochemistry, histology, and scanning electron microscopy.
Results
Preseeding differentiated EPCs demonstrated constant
endothelial phenotypes and showed typical endothelial char-
acteristics including uptake of acetylated low-density lipopro-
tein, cluster of differentiation 31, von Willebrand factor, and
endothelial nitric oxide synthetase. Seeded EPCs revealed
favorable cell-to-polymer attachment and proliferation into
the 3D tubular scaffolds. Both conditioned and static cellular
constructs demonstrated positive staining for cluster of
differentiation 31, von Willebrand factor, and expression of
endothelial nitric oxide synthase.
Conclusions
HUC-derived EPCs demonstrated exceptional growth char-
acteristics. These cells demonstrated a constant endothelial
phenotype and related functional features. Based on these
results EPCs seem to be a promising autologous cell source
regarding cardiovascular tissue engineering, particularly for
the repair of congenital defects.
In the following study, it was recently shown that the
endothelial tissues derived from EPC can be seeded on myofi-
broblasts derived from umbilical cord fibroblasts and finally
form living patches, which can be used as replacements (13).
Future Perspective––Prenatal Harvested Cells
Of particularly importance for the pediatric cardiovascular
tissue engineering is cell-harvesting at early stage that allows
having the tissue-engineered replacement ready for implanta-
tion at the birth of the patient. Therefore, cells should be har-
vested prenatally at an early stage of pregnancy without harming
any intact childish donor structures. As used in routinely pre-
natal diagnostics, both the amniotic fluid and the placenta could
provide the least invasive access to fetal cells (1). Few studies
describe prenatal ewe’s cells from amniotic fluid as a new cell
source for tissue engineering for diaphragma reconstruction in
an animal model.  Kaviani et al. reported the use amniotic fluid-
derived cells obtained at 16–21 wk compared with postnatal
human placental cells obtained from cesarean section delivered
placenta at 33–35 wk of gestation. Recently engineering of liv-
ing autologous pediatric cardiovascular tissue replacements
based on prenatal progenitor cells were investigated (14).
Conclusion
In conclusion hUCC are a promising cell source for car-
diovascular tissue engineering  since they have demonstrated
excellent growth properties and phenotypes similar to the
native counterparts of the tissue they should replace. The HUC
is an excellent and unique source of various types of cells 
(differentiated and nondifferentiated) that can be used for
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A close cooperation between obstetric services (cell har-
vesting and acquisition) and the biotechnical laboratory (cell
processing and tissue engineering) is needed to set up stan-
dards in quantity and quality control, sterility purposes, and
sampling techniques. In addition various factors such as influ-
ence of type of birth (vaginal vs caesarean), vaginal contami-
nation (meconium, bacteria, and so on), influence of maternal
infections, and certainly fetal factors (age, weight, infection,
gender, sex, and so on) have to be closely evaluated (15,16).
At present the effect of crypreservation on the quality of
hUCC as a source of tissue engineering compared with hUCC,
which is immediately processed after birth is investigated.
Further challenges are the clinical and animal application tri-
als, investigation of future cell sources and their viability, opti-
mization of scaffolds, scaled up bioreactors, prevention of tissue
rejection, and product preservation (Table 6). 
Fig. 2. Future perspective and scenario of using hUCC for cardiovascular tissue engineering: after prenatal diagnosis of the cardiovascular defect
(1,2), umbilical cord blood is obtained (3).After isolation and differentiation (4), tissue-engineered constructs are positioned in a biomimetic sys-
tem (5).After tissue maturation is sufficient, heart valves are ready for implantation.
cardiovascular tissue engineering as one example in regener-
ative medicine. There are numerous advantages of these autol-
ogous cells such as high immune tolerance, now major risk of
transmitting bacterial or viral infections, capacity of growth
and remodeling, less risk of thromboembolic complications
and no sacrifice of intact donor structures. 
Table 6
Challenges in Tissue Engineering
• Clinical and animal application trials
• Cost benefit ratio
• Cell sources (healthy, expandable cells)
• Optimization of scaffolds
• Scaled up bioreactors
• Prevention of tissue rejection
• Product preservation
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If most of these questions will be answered, then there is a
great opportunity and perspective to use hUCC for generat-
ing tissue-engineered vessels and heart valves for the repair
of congenital malformations. In a future scenario after prena-
tal diagnosis, fetal cells would be immediately sampled and
processed and the tissue engineered organ would be available
after birth at the time of programmed heart surgery or some
weeks later (Fig. 2).
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